Context Therapeutics (CNTX) Treasury Shares (2020 - 2021)
Context Therapeutics (CNTX) posted Treasury Shares of $16666.0 for Q3 2021, down 99.36% sequentially from $2.6 million in Q2 2021, and down 99.36% YoY from $2.6 million in Q3 2020.
Context Therapeutics (CNTX) Treasury Shares (2020 - 2021) Analysis & Trends
Context Therapeutics has reported Treasury Shares for 2 years, with the latest figure at $16666.0 in Q3 2021.
- Quarterly Treasury Shares fell 99.36% year-over-year to $16666.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $16666.0 (down 99.36% YoY) and the FY2020 annual result came in at $2.6 million, changed N/A from the prior year.
- Treasury Shares declined to $16666.0 in Q3 2021 per CNTX's latest filing, from $2.6 million in the prior quarter.
- Over five years, Treasury Shares peaked at $2.6 million in Q3 2020 and troughed at $16666.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Context Therapeutics | 48.18 Mn | 48.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2021 | 16,666.00 |
| Sep 30, 2021 | 16,666.00 |
| Jun 30, 2021 | 2.62 Mn |
| Jun 30, 2021 | 2.62 Mn |
| Mar 31, 2021 | 2.62 Mn |
| Mar 31, 2021 | 2.62 Mn |
| Dec 31, 2020 | 2.62 Mn |
| Dec 31, 2020 | 2.62 Mn |
| Sep 30, 2020 | 2.62 Mn |
| Sep 30, 2020 | 2.62 Mn |